Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSI1-S347 decoy peptide is a cell-penetrating therapeutic peptide designed to inhibit the phosphorylation of Musashi-1 (MSI1) at the Serine 347 (S347) residue. MSI1 is an RNA-binding protein and oncoprotein that drives tumorigenesis and metastasis in glioblastoma (GBM). The peptide consists of an S347-mimic sequence fused to a TAT protein transduction domain for cellular entry. By acting as a competitive inhibitor, it prevents the phosphorylation of MSI1, which is a critical switch for the expression and localization of matrix metalloproteinases MMP-2 and MMP-9. This inhibition suppresses the epithelial-mesenchymal transition (EMT) and reduces the invasive potential of GBM cells. Developed by researchers at The Hong Kong Polytechnic University, it represents a specific strategy to target MSI1 without affecting its homolog MSI2, which lacks the S347 site.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSI1-S347 decoy peptide.